Osteoarthritis market seen topping $11.84 billion by 2030

The Business Research Company says the global osteoarthritis market is on track to grow at a 10% CAGR through 2030, driven by aging populations, obesity, and treatment innovation. North America and the U.S. are expected to lead the market, while medication remains the biggest treatment segment.

Why it matters: - The osteoarthritis market is projected to reach $11.84 billion by 2030, signaling steady demand for treatments tied to aging, obesity and joint disease. - The category sits within a much larger musculoskeletal drugs market expected to reach about $138 billion by 2030, and the broader pharmaceuticals market expected to hit $2,496 billion. - Medication is expected to remain the largest treatment segment, making up 47% of the market, or about $6 billion, by 2030.

What happened: - The Business Research Company published a 2026 osteoarthritis market report covering market size, trends and forecasts through 2035. - The report says the osteoarthritis market is expected to grow at a 10% compound annual growth rate through 2030. - The report estimates North America will be the largest region in 2030, at $4.3 billion. - The report estimates the U.S. will be the largest country in the market in 2030, at $4.0 billion.

The details: - North America’s market is projected to rise from $2.8 billion in 2025 to $4.3 billion in 2030, at an 8% CAGR. - The U.S. market is projected to grow from $2.7 billion in 2025 to $4.0 billion in 2030, at a 9% CAGR. - Medication growth is expected to be supported by nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying osteoarthritis drugs under development, prescription and over-the-counter pain relief products, targeted biologic therapies and long-term symptom management demand. - The market is also segmented by diagnosis into imaging and joint fluid analysis. - The market is segmented by route of administration into parenteral, topical and oral routes. - The market is segmented by disease type into knee, spine, foot and ankle, shoulder and hand osteoarthritis. - The market’s end-user segment is hospitals and medical institutes. - The report says the medication, therapy and surgery segments together should add more than $5 billion in market value by 2030. - The medication segment is projected to grow by $2 billion, therapy by $2 billion and surgery by $1 billion from 2025 to 2030.

Between the lines: - The forecast points to a market being shaped less by one-time interventions and more by chronic management, repeat care and long-term pain control. - Aging populations and obesity are the clearest demand drivers, but the report also highlights a push toward biologics, regenerative medicine and minimally invasive procedures. - The report’s regional and country concentration suggests commercial opportunities may remain strongest in North America, especially the U.S., where care access and orthopedic infrastructure are expanding.

What's next: - The report expects rising osteoarthritis prevalence and aging populations to contribute 2.2% annual growth. - Obesity and lifestyle-related risk factors are projected to add about 1.9% annual growth. - Advances in treatment technologies and innovative therapies are projected to add roughly 1.7% annual growth. - The company is offering a free sample of the report and access to the full market report through its website: Request a free sample and Access the detailed report.

The bottom line: - Osteoarthritis is emerging as a durable growth market, with North America and medication therapies expected to capture the biggest share of demand by 2030.